MRNA - Moderna Inc Stock Analysis
Moderna Inc (MRNA) is a publicly traded company listed on the NASD. It operates in the Biotechnology industry, part of the broader Healthcare sector. The company has a market capitalization of 20.13B, generates annual revenue of 1.94B, and reports net income of -2.82B. As of the latest data, the stock is trading at 50.96 USD.
From a valuation and risk perspective, the stock presents the following profile: The P/E ratio is unavailable or not meaningful at this time. The PEG ratio is below 1, which may indicate the stock is undervalued relative to its growth potential. The company has very low leverage, which may indicate conservative financial management or underutilization of debt. This stock does not currently pay a dividend. The stock exhibits higher volatility than the market, which may indicate greater risk and potential reward.
Analyst recommendation stands at Sell (2.8), indicating current market sentiment. Institutional ownership is reported at 79.39%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of 108.00%, trading within a 52-week range of 22.28 - 59.55.
MRNA - Moderna Inc
50.96
Analyst Consensus
Sell 2.8
MRNA – Analyst Rating Summary
- Strong Buy: 0
- Buy: 3
- Hold: 21
- Sell: 3
- Strong Sell: 3
- Total Analysts: 30
| Index: | S&P 500 | P/E: | - | EPS (ttm): | -7.26 | Insider Own: | 8.54% | Shs Outstand: | 394.00M | Perf Week: | 3.58% |
| Market Cap: | 20.13B | Forward P/E: | - | EPS next Y: | -4.68 | Insider Trans: | -0.58% | Shs Float: | 361.21M | Perf Month: | -8.95% |
| Income(ttm): | -2.82B | PEG: | - | EPS next Q: | -2.03 | Inst Own: | 79.39% | Short Float: | 16.79% | Perf Quarter: | 50.50% |
| Revenue(ttm): | 1.94B | P/S: | 10.35 | EPS this Y: | 7.43% | Inst Trans: | 6.63% | Short Ratio: | 5.78 | Perf Half Y: | 82.52% |
| Book/sh: | 21.95 | P/B: | 2.32 | EPS next Y: | 30.38% | ROA: | -21.31% | Short Interest: | 60.65M | Perf Year: | 108.00% |
| Cash/sh: | 14.69 | P/C: | 3.47 | EPS next 5Y: | 26.38% | ROE: | -28.87% | 52W Range: | 22.28 - 59.55 | Perf YTD: | 72.80% |
| Dividend Est.: | - | P/FCF: | - | EPS past 3/5Y: | - -29.93% | ROIC: | -28.47% | 52W High: | 59.55 -14.42% | Beta: | 1.21 |
| Dividend TTM: | - | Quick Ratio: | 3.22 | Sales past 3/5Y: | -53.32% 19.33% | Gross Margin: | 44.29% | 52W Low: | 22.28 128.73% | Perf 5Y: | -63.84% |
| Dividend Ex-Date: | - | Current Ratio: | 3.29 | EPS Y/Y TTM: | 21.76% | Oper. Margin: | -158.13% | RSI (14): | 50.77 | Volatility: | 4.33% 5.03% |
| Employees: | 4700 | Debt/Eq: | 0.15 | Sales Y/Y TTM: | -39.93% | Profit Margin: | -145.16% | Recom: | 2.96 | Target Price: | 44.21 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.15 | EPS Q/Q: | 27.57% | Payout: | - | Rel Volume: | 0.60 | Prev Close: | 51.28 |
| Sales Surprise: | 6.75% | EPS Surprise: | 17.07% | Sales Q/Q: | -29.81% | Earnings: | Feb 13 BMO | Avg Volume: | 10.49M | Price: | 50.96 |
| SMA20: | -0.73% | SMA50: | 3.23% | SMA200: | 49.19% | Overbought: 13.25% | Volume: | 6,273,797 | Change: | -0.62% | |
Graham Classic formula value: -399.37
(P/E=8 * 1g) Min value: -224.13
(current P/E * 2g) Max value: -343.95
Average value: -322.48
About Moderna Inc
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.